ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS

• Vial Containment Systems For Gene And Cell Therapies

  CZ vial-stopper-seal combinations offer a viable solution for the challenges associated with low-temperature storage of cell therapy drug products.

• Autoinjectors: A Revolutionary Leap In Drug Delivery

  Explore how the widespread adoption of autoinjectors is transforming the biopharmaceutical industry's approach to drug delivery, offering precise dosing, patient adherence, and safety.

• Is It Ever Too Soon To Start Your Performance Testing Assessment?

  Developing a safe and effective injectable combination product involves performing risk assessments, establishing a set of Critical Quality Attributes (CQAs), and performing design verification testing.

• Liposome Vs. Lipid Nanoparticle: What's The Difference?

  Here, we discuss the differences between nanoparticles and liposomes along with their applications in medicine.

• Enhancing The Solubility Of High Lipophilicity Drugs Via Spray Drying

  A new R&D project shows the solubility and dissolution characteristics of Itraconazole can be improved by helping them maintain an amorphous state after spray drying with selected hydrophilic polymers.

• Navigating PFAS In Medical Devices

  Review how an experienced partner can help you navigate the shifting regulatory landscape for your medical device.

• How To Achieve Precise And Flexible Dosing With Multiparticulates

  For orally delivered medicines, developers often must balance a drug’s “curb appeal” — its specific delivery mechanism, taste, ease of administration, and convenience — with safety and efficacy.

• Solid Form Screening, Rapid Formulation Selection To Meet Tight Timelines

  A comprehensive approach to evaluating drug molecules for the selection of a lead solid form and formulation can significantly accelerate development timelines and limit risks in later development.

• De-Risking The Transition From Vial To Drug-Device Combination Product

  When transitioning from a vial to a combination product system, the best approach is to have a holistic de-risk strategy with an intentional focus on the patient, the plan, and the product.

• Lifecycle Planning For Containment And Delivery Of Biologics Drug Products

  Read more about trends in the biologics market that could impact the lifecycle strategies for your drug product and steps you can take around drug packaging early in development.